Skip to main content

Market Overview

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

Share:
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
  • Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.
  • The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.
  • 2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks. 
  • The combination was well-tolerated. 
  • "Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit," added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. 
  • Enrollment for the trial is stopped.
  • The will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022. 
  • Price Action: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.
 

Related Articles (CORT)

View Comments and Join the Discussion!

Posted-In: Briefs Pancreatic CancerBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com